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Abstract
Background: ExoU, a Pseudomonas aeruginosa cytotoxin with phospholipase A2 activity, was shown to induce
vascular hyperpermeability and thrombus formation in a murine model of pneumosepsis. In this study, we
investigated the toxin ability to induce alterations in pulmonary fibrinolysis and the contribution of the platelet
activating factor (PAF) in the ExoU-induced overexpression of plasminogen activator inhibitor-1 (PAI-1).
Methods: Mice were intratracheally instilled with the ExoU producing PA103 P. aeruginosa or its mutant with
deletion of the exoU gene. After 24 h, animal bronchoalveolar lavage fluids (BALF) were analyzed and lung sections
were submitted to fibrin and PAI-1 immunohistochemical localization. Supernatants from A549 airway epithelial
cells and THP-1 macrophage cultures infected with both bacterial strains were also analyzed at 24 h post-infection.
Results: In PA103-infected mice, but not in control animals or in mice infected with the bacterial mutant, extensive
fibrin deposition was detected in lung parenchyma and microvasculature whereas mice BALF exhibited elevated
tissue factor-dependent procoagulant activity and PAI-1 concentration. ExoU-triggered PAI-1 overexpression was
confirmed by immunohistochemistry. In in vitro assays, PA103-infected A549 cells exhibited overexpression of PAI-1
mRNA. Increased concentration of PAI-1 protein was detected in both A549 and THP-1 culture supernatants. Mice
treatment with a PAF antagonist prior to PA103 infection reduced significantly PAI-1 concentrations in mice BALF.
Similarly, A549 cell treatment with an antibody against PAF receptor significantly reduced PAI-1 mRNA expression
and PAI-1 concentrations in cell supernatants, respectively.
Conclusion: ExoU was shown to induce disturbed fibrin turnover, secondary to enhanced procoagulant and
antifibrinolytic activity during P. aeruginosa pneumosepsis, by a PAF-dependent mechanism. Besides its possible
pathophysiological relevance, in vitro detection of exoU gene in bacterial clinical isolates warrants investigation as a
predictor of outcome of patients with P. aeruginosa pneumonia/sepsis and as a marker to guide treatment
strategies.
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One of the main features of sepsis is the infection-trig-
gered activation of the inflammatory and coagulation
systems. In the lungs, sepsis is associated with increased
permeability of the alveolar/capillary barrier, neutrophil
infiltration and extensive intra-alveolar fibrin deposition
[1]. Changes in pulmonary fibrin turnover are also an
important feature of severe pneumonia demanding
mechanical ventilation and of acute respiratory distress
syndrome (ARDS) [2]. Besides compromising the lung
gas-exchange barrier, excessive alveolar clotting is harm-
ful because surfactant components may be incorporated
into fibrin with subsequent alveolar instability [3].
Pulmonary coagulopathy is the net result of increased
local activation of the coagulation cascade, primarily dri-
ven by the tissue factor (TF) pathway, downregulation of
natural coagulation inhibitors, and overexpression of
plasminogen activator inhibitor-1 (PAI-1), a potent inhi-
bitor of plasminogen activators that activate the fibrino-
lytic system [4]. Studies have shown that impaired
fibrinolysis associated with increased PAI-1 levels in pul-
monary edema fluid correlates with adverse outcomes of
patients with ARDS [5].
Pseudomonas aeruginosa is a prominent agent of
severe ventilator-associated pneumonia and sepsis [6]. A
large body of evidence suggests that proteins delivered
into host cells by the type III secretion system play a
critical role in the pathogenesis of P. aeruginosa-induced
sepsis and ensuing mortality [7]. Evidences are particu-
larly compelling for ExoU, a toxin with phospholipase
A2 (PLA2) activity [7], encoded by about 30% of clinical
and environmental strains [8], and highly cytotoxic to a
range of eukaryotic cells.
PLA2 belongs to a family of enzymes that cleaves the
sn-2 ester bond of phospholipids from mammalian mem-
branes into free unsaturated fatty acids, such as arachido-
nic acid, and lysophospholipids. Released arachidonic
acid can be converted into eicosanoids that play a key
role in the inflammatory process [9]. PLA2 is also crucial
in the synthesis of platelet activating factor (PAF), a
potent proinflammatory mediator [10]. Extensive clinical
and investigational evidences indicate that dysregulated
PAF signalling is involved and, in some cases, may be a
critical determinant of ARDS and sepsis [11,12].
Regulatory mechanisms that control the PAF signal-
ling system include PAF degradation by the enzyme
PAF acetylhydrolases (PAF-AH) [10,13]. PAF-AH gene
contains elements that confer responsiveness to inflam-
matory challenge. Accordingly, the expression of PAF-
AH mRNA and protein can be upregulated by inflam-
matory stimuli, such as bacterial lipopolysaccharide [14],
as well as by PAF itself [15].
We have shown that, due to its PLA2 activity, ExoU
exhibits marked proinflammatory activity [16,17],
induces TF mRNA and protein overexpression by airway
epithelial cells [18] as well as vascular hyperpermeability,
platelet activation and systemic thrombus formation in
P. aeruginosa-infected mice [19]. However, the ability of
ExoU to interfere with the alveolar coagulation/fibrino-
lysis balance has not yet been directly investigated.
In the present study we addressed the question of
whether ExoU would upregulate PAI-1 expression by
airway epithelial cells, and whether PAF would contri-
bute to the generation of the ExoU-induced antifibrino-
lytic environment in mice airways. The current
investigation was further motivated by studies reporting
the PAF ability to activate PAI-1 gene expression by a
PAF receptor (PAFR)-mediated mechanism [20].
Methods
Bacteria
P. aeruginosa PA103 strain and its exoU deficient
mutant PA103ΔexoU [ 1 6 ]w e r eg r o w ni nL u r i a - B e r t a n i
broth at 37°C for 14-16h, harvested by centrifugation
and resuspended in sterile LPS-free saline or culture
medium, as described [19].
Mice infection
Female Swiss mice aged 8-12 weeks were infected intra-
tracheally with 10
4 colony-forming units of PA103 or
PA103ΔexoU in 50 μL of lipopolysaccharide -free saline,
as described [19]. To assess the contribution of PAF in
the procoagulant lung environment, 1 h before the bac-
terial instillation, mice were intraperitoneally inoculated
with the PAFR inhibitor WEB 2086 (Biomol), at a final
dose of 7.5 mg.kg
-1. At 24 h post-infection, animals
were euthanized by intraperitoneal injection of sodium
pentobarbital, and their lungs were flushed with 1 mL of
phosphate buffer saline pH 7.4 (PBS).
Recovered bronchoalveolar lavage fluids (BALF) were
assessed for total cell counting using standard haemo-
cytometer. Cytospin preparations were stained with
Diff-Quick stain (Dade Diagnostics, Inc.) for leukocyte
identification. In other sets of experiments, mice lungs
were fixed in 10% formalin and embedded in paraffin.
A l la n i m a le x p e r i m e n t sw e r eperformed in accordance
with the guidelines of the Animal Ethics Research Com-
mittee of the State University of Rio de Janeiro (protocol
# CEA/210/2007).
BALF analysis
The following commercial kits were used: i) TNF-a and
IL-6 were assayed using DuoSet immunoassay kits
(R&D Systems, ref. DY 410 and DY 406, respectively);
ii) TF-dependent procoagulant activity was assessed with
the Actichrome TF activity assay kit (American Diag-
nostica Inc., ref. 846). Briefly, samples were mixed with
factor VIIa and factor X and incubated at 37°C, allowing
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FVIIa), and the factor X conversion to factor Xa. In the
second stage of the reaction, the amount of factor Xa
generated was measured by its ability to cleave Spectro-
zyme
® Xa, a highly specific chromogenic substrate for
factor Xa, added to the reaction solution. The cleaved
substrate released a chromophore into the reaction solu-
tion. The solution absorbance was read at 405 nm and
compared to those values obtained from a standard
curve generated using known amounts of active TF; iii)
Tissue Factor Pathway Inhibitor (TFPI) was measured
with the IMUBIND Total TFPI ELISA kit (American
Diagnostica Inc, ref. 849); iv) PAI-1 was assayed with
the murine PAI-1 total antigen assay ELISA kit ELISA
kit (Innovative Research, ref. MPAIKT-TOT); v) PAF-
AH activity was measured using a PAF-AH Assay kit,
(Cayman Chemical, ref. 760 901). This assay uses 2-thio
PAF which serves as a substrate for PAF-AH. Upon
hydrolysis of the acetyl thioester bond at the sn-2 posi-
tion by PAF-AH, free thiols are detected using 5,5 -
dithiobis(2-nitrobenzoic acid) supplied by the kit. The
detection range of the assay is from 0.02 to 0.2 μmol/
min/ml of PAF-AH activity which is equivalent to an
absorbance increase of 0.01 to 0.1 per minute.
Immunohistochemical localization of fibrin and PAI-1
Sections of mice lungs embedded in paraffin were
deparaffinized in xylene, hydrated, treated with 10 mM
citrate buffer (pH 6.0) at 95-98°C for 20 minutes for
antigen retrieval, rinsed and treated with a 3% H2O2 in
PBS for 10 minutes at room temperature, to inhibit the
endogenous peroxidase activity. After rinsing in Tris
buffer 0,05M (pH 7.4), sections were incubated over-
night at 4°C with Tris buffer containing 1% bovine albu-
min and then treated with a monoclonal anti-human
fibrin antibody (American Diagnostica Inc., ref. 350) at
1:600 (corresponding to 5,5 μgmL
-1) or a polyclonal
anti-mouse PAI-1 antibody (Innovative Research, ref.
IASMPAI-GF) at 1:4000 (corresponding to 2,5 μg.mL
-1).
After 30 min at 4°C, the sections were rinsed and
immunostained with a biotin free MACH 4™ Universal
horseradish peroxidase-polymer detection kit (Biocare
Medical), following the manufacturer’s instructions. The
reaction was developed using the diaminobenzidine
chromogen kit (Biocare Medical). Sections were stained
with hematoxylin and eosin and analyzed.
Cell cultures
Airway epithelial cells from the A549 line and macro-
phages from the THP-1 line were used to further inves-
tigate the ExoU ability to induce PAI-1 synthesis. The
concentrations of PAI-1 released by control and infected
cells were normalized and reported as pg secreted by
10
5 cells.
A549 cells were seeded (3.0 × 10
4 cells/96 well) in F12
nutrient culture medium (Invitrogen Inc.) containing
10% foetal calf serum (FCS) and antibiotics, cultured for
48 h and infected with PA103 or PA103ΔexoU suspen-
sions at a multiplicity of infection of about 100:1. Bac-
teria were then centrifuged onto cell monolayers (1000
× g for 10 min), to enhance close contact with host
cells. Control cells were exposed to culture medium or,
in some assays, were treated with PAF at 20 μM. mL
-1.
After 1 h at 37°C, control and infected cells were incu-
bated with culture medium containing gentamicin at
300 μg.mL
-1. After 24 h, cell supernatants were recov-
ered for ulterior PAI-1 analysis. In some assays, cells
were treated for 1 h prior to infection with a polyclonal
anti-PAFR antibody (Cayman Chemical Co., ref. 160
602) at 2 μg.mL
-1.
THP-1 cells were seeded (3.0 × 10
4 cells/96 well) in
DMEM medium containing 10% FCS, 1 mM pyruvic
acid, antibiotics and phorbol -12-myristate 13-acetate
(PMA; Sigma-Aldrich) at 40 ng.mL
-1, for the induction
of monocyte-macrophage differentiation [21]. After 3
days, cells were rinsed, cultured in fresh medium with-
out PMA for additional 3 days, infected for 1 h and
treated with the gentamicin-containing culture medium,
as described above. After 24 h, cell supernatants were
recovered for ulterior analysis.
Detection of PAI-1 mRNA by reverse transcriptase-
polymerase chain reaction (RT-PCR)
A549 cells infected for 1 h and treated with the genta-
micin-containing culture medium for additional 17 h
were trypsinized and rinsed to extract total RNA using
Rneasy kit (Qiagen). cDNA was synthesized from total
RNA by reverse transcription using the SuperScript- III
First-Strand synthesis system for RT-PCR (Invitrogen),
and amplified under the following PCR conditions:
denaturation at 94°C for 2 min; and 30 (PAI-1) or 23
(b-actin) cycles of denaturation at 94°C for 45 s, anneal-
ing at 52°C for 45 s and extension at 72°C for 45 s. An
additional extension step of 5 min at 72°C was carried
out after the last cycle. The primers used in the reac-
tions were: 5’-CTG ACT TCA CGA GTC TTT CAG
ACC-3’ (PAI-1 sense); 5’-CCC ATG AAA AGG ACT
GTT CCT GTG-3’ (PAI-1 antisense); 5’-GTT GCT
ATC CAG GCT GTG C-3’ (b-actin sense) and 5’-GCA
TCC TGT CGG CAA TGC-3’ (b-actin antisense). PCR
products were subjected to electrophoresis in a 2% agar-
ose gel and densitometry was performed using Lab-
Image software (Kaplan GmbH, Halle, Germany).
Statistical analysis
Statistical significance was accepted at the P < 0.05 level
by one-way ANOVA for multiple group analysis with a
Bonferroni adjustment.
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ExoU induced a robust inflammatory response in mice
airways
BALF from mice infected with the ExoU-producing
PA103 strain exhibited significantly increased concentra-
tions of inflammatory cells (Figure 1A), IL-6 (Figure 1B)
and TNF a (Figure 1C), confirming the proinflammatory
activity of the toxin.
ExoU also induced a procoagulant and antifibrinolytic
environment in mice airways
BALF from PA103-infected animals exhibited signifi-
cantly elevated TF-dependent procoagulant activity (Fig-
ure 2). ExoU-induced local coagulopathy was confirmed
by the immunohistochemical detection of widespread
fibrin deposition in mice airspaces and lung microvascu-
lature, that was not detected in animals infected with the
ExoU-deficient mutant or in control mice (Figure 3).
Since the balances between the concentrations of TF
and tissue factor pathway inhibitor (TFPI), as well as
between local activation of coagulation and fibrinolysis
are important determinants of alveolar fibrin deposition
[4], we next assessed TFPI and PAI-1 levels in mice
BALF. TFPI was significantly elevated in fluids from ani-
mals infected with both strains (Figure 4A). In contrast,
PAI-1 concentration was significantly elevated only in
BALF from PA103-infected mice (Figure 4B). ExoU-trig-
gered overexpression of PAI-1 was confirmed by immu-
nohistochemical analysis of mice lungs. In PA103-
infected animals, PAI-1 was detected in lung parench-
yma, bronchiolar epithelial cells and type II pneumocytes,
as well as in a fibrillar material that accumulated in the
alveolar compartment. In contrast, in lungs from control
and PA103 ΔexoU-infected animals PAI-1 staining was
restricted to the bronchiolar epithelium (Figure 5).
ExoU modulated PAI-1 release by both airway epithelial
cells and macrophages
PAI-1 concentrations in supernatants from both cell
types infected with the ExoU-producing bacteria were
significantly increased, but the concentrations detected
in A549 cultures was about 30 fold higher than the con-
centrations in macrophage cultures (Figure 6A and 6B).
PAI-1 release by A549 cells in response to ExoU stimu-
lation was also significantly higher than the release
induced by PAF (Figure 6A). Such modulation of PAI-1
release was likely dependent on increased transcription
of the PAI-1 gene since in PA103-infected cells the level
of PAI-1 mRNA was about 20% higher, in comparison
with PA103ΔexoU-infected cells (Figure 6C).
ExoU-induced PAI-1 overexpression was likely dependent
on the PAF signaling system
To address the PAF contribution to PAI-1 release, we
first investigated PAF-AH activity in mice BALF. The
rationale for this approach was that since PAF was
shown to stimulate the promoter activity of PAF-AH
genes [15], and to increase the levels of PAF-AH mRNA
in a dose-dependent manner [22], PAF-AH levels in
host fluids are likely to reflect PAF concentrations.
Since the enzyme activity was highly elevated in fluids
from PA103-infected mice (Figure 7), we next
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Figure 1 ExoU-induced inflammatory environment in mice
airways. Concentrations of total white blood cells (A), IL-6 (B) and
TNF-a (C) in BALF from PA103-infected mice (n = 24) were
significantly higher than concentrations in BALF from control
noninfected mice (n = 21) and from mice infected with the PA103
ΔexoU mutant (n = 21). * p < 0.05, ** p < 0.01 and *** p < 0,001
when mice infected with PA103 were compared with animals from
the other two groups. Data represent mean values ± SE of the
results obtained in three different assays.
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Figure 2 ExoU-induced procoagulant activity in mice airways.
Tissue factor dependent procoagulant activity was significantly
increased in BALF from PA103-infected mice. ** p < 0,01 and *** p
< 0,001 when mice infected with PA103 (n = 12) were compared
with those infected with the bacterial mutant (n = 10) or with
control mice (n = 10). Data represent mean values ± SE of the
results obtained in three different assays.
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on PAI-1 secretion. Figure 8A shows that WEB-2086
reduced significantly the PAI-1 levels in BALF from
PA103-infected mice. We also observed a significant
reduction of total leukocyte concentration (Figure 8B)
and TF dependent procoagulant activity (Figure 8C) in
fluids from mice infected with the ExoU-producing bac-
teria pretreated with the PAF antagonist.
T h er o l eo fP A Fi nP A I - 1o v e r e x p r e s s i o nw a sf u r t h e r
demonstrated in in vitro assays. As shown in Figure 9,
cell treatment with an anti-PAFR antibody prior to
PA103 infection resulted in a significant reduction of
both PAI-1 mRNA expression and PAI-1 concentration
in cell culture supernatants. These results further sup-
port the contribution of the PAF signalling system in
the ExoU-induced antifibrinolytic environment in mice
airways.
Discussion
This study demonstrated that ExoU enhances the fol-
lowing adverse events in the course of P. aeruginosa
pneumosepsis: i) fibrin deposition in mice lung parench-
yma; ii) alveolar TF-dependent procoagulant activity
that did not depend on decreased TFPI production; iii)
generation of an antifibrinolytic environment, secondary
to increased PAI-1 production. The study also
Figure 3 Immunohistochemical localization of fibrin. Lung sections from control mice (A) and PA103 ΔexoU-infected mice (B) exhibited
minimal infiltration of inflammatory cells in interalveolar septum (arrow in B) and barely detectable fibrin staining. In sections from mice infected
with the ExoU-producing bacteria, dark brown stained fibrin was detected all over the lung parenchyma (C; asterisk). Photomicrographs D-F
exhibit higher magnifications of sections from PA103-infected mice. Arrows point to fibrin deposition in interalveolar septum (D) and inside
blood vessels (E and F). Note in F, the huge edema in interalveolar space (asterisks). Original magnifications: A-C, × 20; D-F, × 100.
Photomicrographs are representative of sections from seven animals from each group.
Control
PA103
exoU
Δ
PA103
0
5
10
15
20
25
***
**
 
P
A
I
 
(
n
g
.
m
L
-
1
)
Control
PA103
exoU
Δ
PA103
0.0
0.1
0.2
0.3
0.4
0.5
0.6
*
**
 
T
F
P
I
 
 
(
n
g
.
m
L
-
1
)
AB
Figure 4 ExoU-induced antifibrinolytic activity in mice airways.
In (A) it is shown that TFPI concentrations in BALF from mice
infected with PA103 (n = 12) and PA103ΔexoU (n = 12) were
significantly higher than concentrations in BALF from control mice
(n = 13), but did not differ from each other. * p < 0.05 and ** p <
0.01 when infected mice were compared with control mice. In
contrast, in (B) it is shown that PAI-1 concentration in BALF from
mice infected with the ExoU-producing PA103 was significantly
increased. ** p < 0.01 and *** p < 0,001 when mice infected with
PA103 were compared with those infected with the bacterial
mutant or with control mice. Data represent mean values ± SE of
the results obtained in three different assays.
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ling system in ExoU-induced PAI-1 overproduction.
Collectively, our results provide evidence of a novel
mechanism that may contribute to the reported poor
outcome of patients with severe infection by ExoU-pro-
ducing P. aeruginosa [23].
Increased expression of TF has been widely reported
to play a crucial role in initiating intra-alveolar coagula-
tion and fibrin deposition in patients with ARDS
[24,25]. The recently reported ability of ExoU to induce
overexpression of TF mRNA and protein both in vitro
and in vivo [18] may possibly be one of the key determi-
nants of the currently described procoagulant activity in
BALF from PA103-infected mice.
Mechanisms that regulate the coagulation pathway
include TFPI, the sole endogenous TF inhibitor so far
described. Studies have shown that the alveolar epithe-
lium can regulate the release of TFPI into the air spaces
in response to inflammatory stimuli [26]. Consistent
with this idea, substantially increased TFPI concentra-
tions were reported in BALF from patients at risk and
with established ARDS [26]. Similarly, in our study, ele-
vated TFPI levels were detected in BALF from mice
infected with both P. aeruginosa strains but, in mice
infected with the ExoU-producing bacteria, levels of
alveolar TFPI were not sufficient to overcome the
intense TF procoagulant activity induced by the bacter-
ial toxin. A possible explanation for this insufficiency is
the degradation of TFPI through the action of proteases
found in the inflamed air spaces [27,28]. Indeed, the
majority of TFPI detected in BALF from patients with
ARDS was reported to be in inactive form [29].
A second mechanism that could contribute to the
alveolar coagulopathy detected in PA103-infected mice
is the impairment of the fibrinolytic activity, described
in fluids from patients with ARDS [30], primarily attri-
butable to increased PAI-1 expression [31]. The impor-
tance of upregulated PAI-1 levels as a marker of lung
disease was recently substantiated by its recognition as a
biomarker allowing the distinction between colonization
and ventilator-associated pneumonia in mechanically
ventilated patients [32].
In a recent investigation, high levels of PAI-1 detected
in BALF from patients with P. aeruginosa ventilator-
associated pneumonia/ARDS correlated with the pro-
duction of type III ExoS and ExoU toxins by the infect-
ing bacteria. Interestingly, patients infected with ExoU
secreting strains had the highest PAI-1 levels [33]. This
present study, which is the first to directly address the
ability of ExoU to modulate PAI-1 expression, con-
firmed the existence of a positive relationship between
ExoU expression and increased PAI-1 production in
vivo and in vitro.
In this report, we also examined the role of PAF in
ExoU-induced PAI-1 overexpression. The rationales
were: i) cell intoxication with ExoU is likely to induce
increased production of PAF because PAF synthesis by
the remodelling pathway is initiated by the activity of
Figure 5 Immunohistochemical localization of PAI-1. In lung sections from control mice (A) and from mice infected with the bacterial
mutant (B) PAI-1 staining was almost resctricted to the bronchiolar epithelium (arrows). Sections from mice infected with the ExoU-producing
bacteria exhibited dark brown diaminobenzidine signals in intraalveolar fibrilar material reminiscent of hyaline membrane (arrows in C and E)
and in type II pneumocytes (arrows in D). Original magnification: A-B, × 20; C, × 40; D and E, × 100. Photomicrographs are representative of
sections from seven animals from each group.
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is an inducer of PAI-1 gene expression [20].
To explore this possibility, it would have been ideal to
demonstrate increased levels of PAF in BALF from
PA103-infected mice. However, given the unstable nat-
ure of PAF, it is often problematic to measure this
molecule in vivo. On the other hand, upregulation of
PAF-AH expression is an important mechanism of PAF
inactivation [14]. Since PAF itself is a potent inducer of
PAF-AH release [15,22], PAF levels in mice BALF was
indirectly estimated by the activity of PAF-AH, reported
to be elevated in BALF from patients with ARDS [34].
Our finding that PAF-AH activity was greatly increased
in fluids from PA103-infected mice was taken as an evi-
dence of increased pulmonary PAF levels. Moreover,
our results showing that a PAF antagonist reduced sig-
nificantly the concentration of inflammatory cells and
the procoagulant activity of BALF from PA103-infected
mice were taken as a definitive evidence of increased
levels of PAF induced by the ExoU-producing P. aerugi-
nosa strain. Since PA103 and PA103ΔexoU only differ
from each other in their ability to produce ExoU, we
concluded that this toxin, and not LPS or another bac-
terial PAMP, accounted for increased PAF levels in
mice airways. To our knowledge, this is the first report
of a relationship between ExoU and PAF generation.
Further studies are necessary to determine the role such
PAF generation in the pathogenesis of P. aeruginosa
infection.
Consistent with our hypothesis that PAF is involved in
the control of PAI-1 production, treatment with the
PAF antagonist significantly reduced PAI-1 levels in
fluids from PA103-infected animals although the
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Figure 6 Enhanced in vitro PAI-1 production by PA103-infected
cells. PAI-1 concentrations in supernatants from A549 epithelial
respiratory cells (A) and THP-1 macrophages (B) infected with the
ExoU-producing PA103 were significantly higher than
concentrations detected in supernatants from control noninfected
cells or from cells infected with the PA103 exoU mutant. Data
represent mean values ± SE of the results obtained in three
different assays carried out in quintuplicate. **p < 0.01 and *** p <
0,001 when data obtained from PA103-infected cells were
compared with data from control cells and from PA104ΔexoU-
infected cells, or when data obtained with PAF-treated cells were
compared with those from control cells. In (C), a representative
agarose gel shows the expression of PAI-1 and b-actin mRNA
transcripts in control and infected A549 cells assessed by
semiquantitative RT-PCR. In (D), mean ± SD values of the ratio of
PAI-1 to b-actin transcript densities obtained in 2 RT-PCR assays
carried out in duplicate. *, p < 0.05 and ** p < 0.01 when data
obtained from PA103-infected cells were compared with those from
controls and from PA103ΔexoU-infected cells.
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Figure 7 BALF from PA103-infected mice exhibited increased
PAF-AH activity. PAF-AH activity in BALF from mice infected with
the ExoU-producing bacteria (n = 13) was significantly higher than
in BALF from control mice (n = 12) or from animals infected with
the bacterial mutant (n = 13). ** p < 0,01 and *** p < 0,001 when
mice infected with PA103 were compared with animals from the
other two groups. Data represent mean values ± SE of the results
obtained in three different assays.
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Page 7 of 10reduction was only partial. The biological effects of PAF
are mediated by binding to a cell receptor [11] that is
upregulated by inflammatory stimuli [35]. Indeed,
ongoing immunocytochemical studies from our group
have shown that PAFR is overexpressed in lung sections
from PA103-infected mice (unpublished data). So, the
inability to demonstrate a substantial inhibition of the
ExoU-induced PAI-1 overproduction may have stemmed
from difficulties in completely blocking the heavy
expression of PAFR with the competitive inhibitor.
Since mice could not be treated with higher concen-
trations of the PAF antagonist, we further investigated
our hypothesis by treating epithelial respiratory cells
with an antibody against PAFR prior to infection. Strik-
ingly, after cell treatment, the expression of PAI-1
mRNA by PA103-infected cells and the PAI-1 concen-
trations in cell culture supernatants were reduced to
levels that did not differ from those detected in superna-
tants from control cells or from cells infected with the
bacterial mutant.
Conclusion
Our results support the hypothesis that, due to its pro-
coagulant/antifibrinolytic activity, ExoU is implicated in
the pathogenesis of severe sepsis and ARDS caused by
P. aeruginosa.
Over the past years, studies have shown that detection
of specific biomarkers in airspaces and plasma may
favor the early detection of lung injury, the risk stratifi-
cation of patient enrolled in clinical trials and the defini-
tion of specific therapies to individual patients [36].
Based on our results, we believe that in vitro detection
of exoU gene in clinical isolates deserves to be investi-
gated as a predictor of patient outcome and a marker to
guide treatment strategies.
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PA103-infected cells. In (A), a representative agarose gel shows
the expression of PAI-1 and b-actin mRNA transcripts in control and
infected A549 cells pretreated or not with the anti-PAFR antibody,
assessed by semiquantitative RT-PCR. In (B), mean ± SD values of
the ratio of PAI-1 to b-actin transcript densities obtained in 2 RT-
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PAFR antibody, obtained in three different assays carried out in
quintuplicate. *** p < 0,001 when the results from PA103-infected
cells pretreated with anti-PAFR antibody were compared with those
from untreated cells or when data obtained from PA103-infected
cells were compared with those from controls or from PA103ΔexoU-
infected cells.
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Figure 8 Effects of mice treatment with the PAF antagonist
WEB 2086. Mice treatment with a PAF antagonist reduced
significantly the concentrations of PAI-1 (A) and of inflammatory
cells (B), as well as the procoagulant activity (C) detected in BALF
from mice infected with the ExoU-producing PA103 bacteria. * p <
0,05, **, p < 0.01 and *** p < 0,001 when the results from PA103-
infected mice pretreated with WEB (WEB +) were compared with
those from untreated mice (WEB -), or when data obtained from
PA103-infected mice were compared with those from controls or
from PA103ΔexoU-infected animals. Each group contained at least
11 animals. Data represent mean values ± SE of the results obtained
in three different assays.
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